StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
6431.TW$18.65-1.06%
Fair $18.65+0.0%

6431.TW

Kuangli Bio-Tech Holdings Co., Ltd.

Consumer Defensive / Household & Personal ProductsTaiwan

$18.65

-0.20 (-1.06%)

Fairly Valued+0.0%Fair Value $18.65Fund rank 28/100 · Data gapFallback financials|
SA 15/F
F-Score: 3/9
Low Profitability

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 33% · confianza 22%

FCF escenarios

weak_data · normalized FCF $-87.6M · quality 62.3/100

Data gap 28/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 37/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

15/100

F

Piotroski

3/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 1unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Sector-specific holding-company NAV/SOTP model required: targets are disabled until look-through holdings, debt and discount data exists. ROE is -33.4%, below the 5% threshold
Thesis & Journal · 6431.TWLocal privado en este navegador · Kuangli Bio-Tech Holdings Co., Ltd.
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$1.8B

P/E

N/A

•

EV/EBITDA

N/A

•

ROE

-33.4%

↓

Gross Margin

18.7%

↓

Debt/Equity

0.84

↑
52-Week Range$19
$15$32

TradingView lightweight chart

6431.TW price, volumen y niveles de valoración

Último $18.65Periodo -40.2%
Fair value: $18.65

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

+3.3%

FCF CAGR

—

FCF margin

-41.0%

FCF / Net income

0.80x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $377.0M · net income $-193.0M · FCF $-154.5M

2022-FY → 2025-FY

Gross margin

18.7%-1.4% pts

Operating margin

-39.4%-13.5% pts

Net margin

-51.2%-31.1% pts

FCF margin

-41.0%-28.3% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$377.0M$377.0M$381.3M$293.4M$342.2M
Net Income$-193.0M$-193.0M$-172.8M$-104.2M$-68.7M
EBITDA$-92.5M$-92.5M$-82.6M$-48.9M$-9.5M
EPS——-2.52-1.82-1.22
Gross Margin18.7%18.7%17.9%22.6%20.1%
Operating Margin-39.4%-39.4%-36.2%-39.0%-25.9%
Net Margin-51.2%-51.2%-45.3%-35.5%-20.1%
Balance Sheet
Debt/Equity0.840.840.730.760.52
Current Ratio1.221.22———
Cash Flow
Free Cash Flow$-154.5M$-154.5M$-82.7M$-87.6M$-43.5M
Returns
ROE-33.4%-33.4%-37.6%-18.7%-10.2%
Valuation
P/B3.153.152.201.711.71
Growth & Yield
Revenue Growth-1.1%-1.1%30.0%-14.3%—
EPS Growth——-38.5%-49.2%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%
Reverse DCF requires positive EPS; loss-making or zero-EPS companies cannot produce a clean EPS hurdle.

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total +1.4%

Total return

+1.4%

Start / end P/E

n/dx → n/dx

EPS bridge

-2.52 → n/d

Residual

+1.4%

EPS growthn/d
Multiple reratingn/d
Dividend+0.0%
Residual / FX / buybacks / cross-term+1.4%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.